C/EBPα expression or activity is commonly diminished in acute myeloid leukemia (AML) cases, including CEBPA point mutations impacting trans-activation or DNA-binding, RUNX1-ETO expression reducing CEBPA transcription, and C/EBPα(S21) phosphorylation also impairing trans-activation [5]. This evidence concerns the gene CEBPA and acute myeloid leukemia.